Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
David Planchard, Pasi A. Jänne, Ying Cheng, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 21, pp. 1935-1948
Closed Access | Times Cited: 248

Showing 1-25 of 248 citing articles:

Exploring treatment options in cancer: Tumor treatment strategies
Beilei Liu, Hongyu Zhou, Licheng Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 162
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, et al.
Cell (2024) Vol. 187, Iss. 7, pp. 1617-1635
Open Access | Times Cited: 127
Lung cancer in patients who have never smoked — an emerging disease
Jaclyn LoPiccolo, Alexander Gusev, David C. Christiani, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 2, pp. 121-146
Open Access | Times Cited: 69
CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer
Pasi A. Jänne, David Planchard, Kunihiko Kobayashi, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 808-820
Open Access | Times Cited: 54
Non-small-cell lung cancer
Lizza Hendriks, Jordi Remón, C. Faivre‐Finn, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 43
New promises and challenges in the treatment of advanced non-small-cell lung cancer
May-Lucie Meyer, Bailey G Fitzgerald, Luís Paz-Ares, et al.
The Lancet (2024) Vol. 404, Iss. 10454, pp. 803-822
Closed Access | Times Cited: 38
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
Enriqueta Felip, Byoung Chul Cho, Valentín García‐Gutiérrez, et al.
Annals of Oncology (2024) Vol. 35, Iss. 9, pp. 805-816
Open Access | Times Cited: 25
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. e1-e22
Closed Access | Times Cited: 24
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, G.M. Marinato, C. Mulargiu, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104295-104295
Open Access | Times Cited: 21
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.1
Dwight H. Owen, Nofisat Ismaila, Janet Freeman‐Daily, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. e44-e59
Closed Access | Times Cited: 20
Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study
Collin M. Blakely, Anatoly Urisman, Matthew A. Gubens, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 26, pp. 3105-3114
Open Access | Times Cited: 17
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 8, pp. 989-1002
Closed Access | Times Cited: 16
KRAS G12C inhibitor combination therapies: current evidence and challenge
Hirotaka Miyashita, Shumei Kato, David S. Hong
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 15
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation–Positive Non–Small Cell Lung Cancer (BLOSSOM)
Sehhoon Park, Richard Baldry, Hyun Ae Jung, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 23, pp. 2747-2756
Open Access | Times Cited: 14
ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer
Aakash Desai, Tadana A. Vázquez, Keishla M. Arce, et al.
Cancers (2024) Vol. 16, Iss. 5, pp. 940-940
Open Access | Times Cited: 13
NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy
Leona Rašková Kafková, Joanna Maria Mierzwicka, Prosenjit Chakraborty, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 10
Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect
Conghua Lu, Ziyuan Gao, Di Wu, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 6, pp. e009165-e009165
Open Access | Times Cited: 10
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database
Kaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. 1539-1549
Closed Access | Times Cited: 10
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Fei Zhou, Haoyue Guo, Yang Xia, et al.
Nature Reviews Clinical Oncology (2024)
Closed Access | Times Cited: 10
Self-improving generative foundation model for synthetic medical image generation and clinical applications
Jinzhuo Wang, Kai Wang, Yunfang Yu, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 10
Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
Carla Corvaja, Antonio Passaro, Ilaria Attili, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102824-102824
Closed Access | Times Cited: 9
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR -Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
Xiuning Le, Jyoti D. Patel, Elaine Shum, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 9
TP53 gain-of-function mutations promote osimertinib resistance via TNF-α–NF-κB signaling in EGFR-mutated lung cancer
Ritsu Ibusuki, Eiji Iwama, Atsushi Shimauchi, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 8
Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
Takehiro Tozuka, Rintaro Noro, Hideaki Mizutani, et al.
Lung Cancer (2024) Vol. 191, pp. 107540-107540
Closed Access | Times Cited: 8
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)
Huajun Chen, Hai‐Yan Tu, Yanping Hu, et al.
Journal of Hematology & Oncology (2025) Vol. 18, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top